Abstract B44: Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells

Chara Stavraka(King's College London), Sarah P. Blagden(Churchill Hospital), Benedikt M. Kessler(University of Oxford), Laki Buluwela(The London College), Manuela Mura(Ovarian Cancer Action), James Chettle(University of Oxford), Sadaf Ghaem Maghami(The London College), Marie‐Laëtitia Thézénas(University of Oxford), Román Fischer(University of Oxford)

Cancer Research

March 14, 2017

10.1158/1538-7445.transcontrol16-b44

Cited by 1

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

|Nature Immunology|2020|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Performance status score: do patients and their oncologists agree?

|British Journal of Cancer|2003|222

Structural basis and specificity of human otubain 1-mediated deubiquitination

|Biochemical Journal|2008|206